Clinical trial Recruiting at 1 site Observational Ages 18 to 65 Women only

Interoceptive Sensitivity and Central Sensitization in Fibromyalgia

Official title: Association Between Interoceptive Sensitivity and Central Sensitization Symptom Burden in Women With Fibromyalgia: A Cross-Sectional Study

Run by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · NCT07878286 · Data updated 2026-11-12

This study tests how people with fibromyalgia perceive internal bodily signals and whether that relates to their symptom burden.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexWomen only
Enrollment110 (estimated)
SponsorSultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Academic / other
Locations1 site (Istanbul)
StatusRecruiting
StartedSeptember 9, 2026
Main results expectedJanuary 15, 2027
Study endsJanuary 15, 2027
Registry record updatedOctober 16, 2026
Trial IDNCT07878286 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–65 with fibromyalgia (per 2016 ACR criteria) experiencing widespread pain for at least 3 months and able to complete questionnaires.

Probably not a fit

Individuals outside the inclusion criteria or with conditions that prevent completing study assessments may not benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cross-sectional observational study investigates the relationship between interoceptive sensitivity and central sensitization symptom severity in adults with fibromyalgia. Participants will complete standardized assessments for interoception, pain, fatigue, sleep quality, anxiety, and depression, and the connections among these measures will be analyzed. The goal is to clarify how internal bodily perception relates to fibromyalgia symptoms and to lay groundwork for future longitudinal or interventional work. Interventions used in this study include the Central Sensitization Inventory, the Multidimensional Assessment of Interoceptive Awareness (MAIA-2), the Revised Fibromyalgia Impact Questionnaire, a numeric rating scale for pain, and the Hospital Anxiety and Depression Scale. The study is conducted at Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Turkey, with female adults aged 18–65 who meet diagnostic criteria and consent to participate.

Why it matters

Potential benefit: If successful, results could improve understanding of symptom drivers in fibromyalgia and guide more targeted approaches to managing interoceptive and central sensitization-related symptoms.

How similar studies have gone: Prior work in related areas suggests links between interoception and chronic pain, but this exact cross-sectional focus in fibromyalgia is relatively novel and exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women patients aged 18-65
* Diagnosed with fibromyalgia according to the 2016 ACR criteria
* Experiencing widespread pain for at least 3 months
* Having the cognitive ability to complete the scales
* Having read and signed the informed consent form (ICF)

Exclusion Criteria:

* Being under 18 or over 65 years old
* Pregnancy
* Active inflammatory rheumatic disease
* Neurological disease
* Malignancy
* Severe psychiatric disorder
* Serious systemic disease such as heart or kidney failure

Where it's running

  • Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi
    Istanbul, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.